These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 15455382

  • 1. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R.
    Int J Cancer; 2005 Jan 20; 113(3):372-8. PubMed ID: 15455382
    [Abstract] [Full Text] [Related]

  • 2. The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma.
    Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, Bar-Shavit R.
    Gynecol Oncol; 2006 Dec 20; 103(3):802-6. PubMed ID: 16875721
    [Abstract] [Full Text] [Related]

  • 3. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH, Chan KY, Khoo US, Ngan HY, Xue WC, Chiu PM, Ip P, Cheung AN.
    Carcinogenesis; 2005 Apr 20; 26(4):855-63. PubMed ID: 15677627
    [Abstract] [Full Text] [Related]

  • 4. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR.
    Cancer Cell; 2007 Apr 20; 11(4):321-33. PubMed ID: 17418409
    [Abstract] [Full Text] [Related]

  • 5. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS.
    Oncogene; 2007 Feb 01; 26(5):683-700. PubMed ID: 16878154
    [Abstract] [Full Text] [Related]

  • 6. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.
    Oncol Rep; 2004 Jun 01; 11(6):1153-9. PubMed ID: 15138549
    [Abstract] [Full Text] [Related]

  • 7. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.
    Lancet Oncol; 2013 Aug 01; 14(9):853-62. PubMed ID: 23845225
    [Abstract] [Full Text] [Related]

  • 8. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
    Gyftaki R, Liacos C, Politi E, Liontos M, Saltiki K, Papageorgiou T, Thomakos N, Haidopoulos D, Rodolakis A, Alevizaki M, Bamias A, Dimopoulos A.
    Int J Gynecol Cancer; 2014 Jun 01; 24(5):851-6. PubMed ID: 24844218
    [Abstract] [Full Text] [Related]

  • 9. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
    Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM.
    Am J Pathol; 2009 May 01; 174(5):1597-601. PubMed ID: 19349352
    [Abstract] [Full Text] [Related]

  • 10. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B.
    Cancer; 2005 Apr 15; 103(8):1631-43. PubMed ID: 15742334
    [Abstract] [Full Text] [Related]

  • 11. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
    Bi SN, Dai SZ, Yao Q, Che YC, Wang N.
    Zhonghua Zhong Liu Za Zhi; 2008 Apr 15; 30(4):288-91. PubMed ID: 18788634
    [Abstract] [Full Text] [Related]

  • 12. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y.
    Oncol Rep; 2011 Apr 15; 25(4):1131-8. PubMed ID: 21249319
    [Abstract] [Full Text] [Related]

  • 13. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
    Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC.
    Gynecol Oncol; 2007 Aug 15; 106(2):311-7. PubMed ID: 17532031
    [Abstract] [Full Text] [Related]

  • 14. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, Xie D.
    Carcinogenesis; 2010 Sep 15; 31(9):1576-83. PubMed ID: 20668008
    [Abstract] [Full Text] [Related]

  • 15. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
    Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, Okuda H, Kudo T.
    Anticancer Res; 2001 Sep 15; 21(4B):2983-7. PubMed ID: 11712798
    [Abstract] [Full Text] [Related]

  • 16. B7-H4 overexpression in ovarian tumors.
    Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.
    Gynecol Oncol; 2006 Jan 15; 100(1):44-52. PubMed ID: 16256178
    [Abstract] [Full Text] [Related]

  • 17. Increased expression of protease M in ovarian tumors.
    Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ.
    Tumour Biol; 2001 Jan 15; 22(1):11-8. PubMed ID: 11054022
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene.
    Horiuchi A, Hayashi T, Kikuchi N, Hayashi A, Fuseya C, Shiozawa T, Konishi I.
    Int J Cancer; 2012 Oct 15; 131(8):1755-67. PubMed ID: 22287060
    [Abstract] [Full Text] [Related]

  • 19. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion.
    Barbolina MV, Adley BP, Shea LD, Stack MS.
    Cancer; 2008 Apr 01; 112(7):1632-41. PubMed ID: 18260155
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
    Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC.
    Gynecol Oncol; 2008 May 01; 109(2):234-9. PubMed ID: 18331757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.